SCHEMBL4866016

SCHEMBL4866016

CCCCCCCCOc1ccc(-c2ccc(O)c(F)c2F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR5A1 Q13285 1/20 0.55
RARB P10826 3/20 0.50
LTA4H P09960 2/20 0.49
PTPN11 Q06124 2/20 0.48
TP53 P04637 2/20 0.47
TSHR P16473 1/20 0.47
MCL1 Q07820 1/20 0.46
PLA2G4B P0C869 1/20 0.46
HTR2A P28223 2/20 0.44
HTR2C P28335 2/20 0.44
CNR2 P34972 2/20 0.44
HTR1B P28222 1/20 0.44
HTR2B P41595 1/20 0.44
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9405815 1.00 NR5A1 (0.55) NR5A1RARBLTA4HPTPN11TP53
SCHEMBL8992927 1.00 NR5A1 (0.55) NR5A1RARBLTA4HPTPN11TP53
SCHEMBL4869927 0.99 NR5A1 (0.54) NR5A1RARBLTA4HPTPN11TP53
SCHEMBL9419290 0.99 NR5A1 (0.53) NR5A1RARBLTA4HPTPN11TP53
SCHEMBL1575262 0.96 MCL1 (0.49) NR5A1RARBLTA4HPTPN11MCL1
SCHEMBL9494586 0.91 NR5A1 (0.56) NR5A1RARBLTA4HPTPN11TP53
SCHEMBL9494594 0.91 NR5A1 (0.56) NR5A1RARBLTA4HPTPN11TP53
SCHEMBL9494141 0.91 NR5A1 (0.56) NR5A1RARBLTA4HPTPN11TP53
SCHEMBL9496980 0.91 NR5A1 (0.56) NR5A1RARBLTA4HPTPN11TP53
SCHEMBL9494660 0.91 NR5A1 (0.56) NR5A1RARBLTA4HPTPN11TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462587-B2 Composition for removing a film from a substrate, a method of removing a film from a substrate, and a method of making the composition GENERAL CHEMICAL CORP (US) 2008-12-09 US disclosed
US-7351452-B2 Liquid crystalline compounds containing a biphenyl core QINETIQ LIMITED (GB) 2008-04-01 US disclosed
WO-2005108536-A2 A COMPOSITION FOR REMOVING A FILM FROM A SUBSTRATE, A METHOD OF REMOVING A FILM FROM A SUBSTRATE, AND A METHOD OF MAKING THE COMPOSITION GENERAL CHEMICAL CORPORATION (US) 2005-11-17 WO disclosed
US-20050245412-A1 Composition for removing a film from a substrate, a method of removing a film from a substrate, and a method of making the composition GENERAL CHEMICAL CORPORATION 2005-11-03 US disclosed
US-20050001200-A1 Liquid crystalline compounds containing a biphenyl core QINETIQ LIMITED (GB) 2005-01-06 US disclosed
WO-2003040074-A1 LIQUID CRYSTALLINE COMPOUNDS CONTAINING A BIPHENYL CORE QINETIQ LIMITED (GB) 2003-05-15 WO disclosed
US-6436312-B1 FERROELECTRIC DISPLAYS COMPRISING DOPES AND MIXTURES OF ESTERS OR FLUORINE COMPOUNDS, EXHIBITING TEMPERATURE DEPENDENT TIME-VOLTAGE CURVES SHARP KABUSHIKI KAISHA (JP) 2002-08-20 US disclosed
US-5545747-A STABLE FERROELECTRIC LIQUID CRYSTALLINE COMPOUNDS KANTO KAGAKU KABUSHIKI KAISHA (JP) 1996-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050001200-A1 Liquid crystalline compounds containing a biphenyl core YBX1, AFF1, AFF2 NR5A1 676/4885RARB 1075/4885LTA4H 3349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.